Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 5/2007

01-09-2007

Low Level of IGF-1 in Obesity May Be Related to Obstructive Sleep Apnea Syndrome

Authors: Ahmet Ursavas, Mehmet Karadag, Yesim Ozarda Ilcol, Ilker Ercan, Basak Burgazlioglu, Funda Coskun, R. Oktay Gozu

Published in: Lung | Issue 5/2007

Login to get access

Abstract

The aim of this study was to compare serum insulin-like growth factor (IGF-1) levels in patients with obstructive sleep apnea syndrome (OSAS) with those of nonapneic controls and to determine the risk factors of low IGF-1 levels in patients with OSAS. The study included 39 newly diagnosed moderate-to-severe OSAS patients and 36 nonapneic controls. Overnight polysomnography (PSG) was performed in all patients. The circulating levels of IGF-1 in the OSAS group were significantly lower than those of the control group (p < 0.05). There was a significant negative correlation between IGF-1 and logarithmic transformation (Ln) of the apnea-hypopnea index (AHI), duration of apnea-hypopnea, arousal index, average desaturation, and oxygen desaturation index (ODI). The result of stepwise regression analyses showed that OSAS (p = 0.001) was a risk factor for a low IGF-1 level, independent of age, gender, and body mass index (BMI). Our findings demonstrated that there was a significant negative correlation between IGF-1 and Ln AHI and that OSAS reduced the circulating levels of IGF-1.
Literature
1.
Hedner J, Grote L (1998) Cardiovascular consequences of obstructive sleep apnea. Eur Respir Mon 10:227–265
2.
Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, Kales A (2001) Prevalence of sleep disordered breathing in women; effects of gender. Am J Respir Crit Care Med 163:608–613PubMed
3.
4.
Tapanainen P, Knip M (1992) Evaluation of growth hormone secretion and treatment. Ann Med 24:237–247PubMed
5.
Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB (1993) Serum levels of insulin like growth factor I (IGF-I) and IGF binding protein 3 reflects spontaneous growth hormone secretion. J Clin Endocrinol Metab 76:1610–1616PubMedCrossRef
6.
Engström BE, Karlsson FA, Wide L (1999) Gender differences in diurnal growth hormone and epinephrine values in young adults during ambulation. Clin Chem 45:1235–1239PubMed
7.
Minuto F, Barreca A, Del Monte P, Fortini P, Resentini M, Morabito F, Giordano G (1988) Spontaneous growth hormone and somatomedin-C/insulin like growth factor-I secretion in obese subjects during puberty. J Endocrinol Invest 11:489–495PubMed
8.
Bernstein D, Jasper JR, Rosenfeld RG, Hintz RL (1992) Decreased serum insulin like growth factor-I associated with growth failure in newborn lambs with experimental cyanotic heart disease. J Clin Invest 89:1128–1132PubMedCrossRef
9.
Gronfier C, Luthringer R, Follenius M, Schaltenbrand N, Macher JP, Muzet A, Brandenberger G (1996) A quantitative evaluation of the relationships between growth hormone secretion and delta wave electroencephalographic activity during normal sleep and after enrichment delta waves. Sleep 19:817–824PubMed
10.
Bayes-Genis A, Conover CA, Schwartz RS (2000) The insulin like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 86:125–130PubMed
11.
Rechtschaffen A, Kales A (eds) (1973) A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects, 3rd ed. Los Angeles: Brain Research Institute, pp 1–13
12.
Xu Y, Li S, Huang X, Cong B (2002) Insulin like growth factor-I and cognitive function in patients with obstructive sleep apnea syndrome. Zhonghua Yi Xue Za Zhi 82:1388–1390PubMed
13.
McArdle N, Hillman D, Beilin L, Watts G (2007) Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 175:190–195PubMedCrossRef
14.
Gianotti L, Pivetti S, Lanfranco F, Tassone F, Navone F, Vittori E, Rossetto R, Gauna C, Destefanis S, Grottoli S, De Giorgi R, Gai V, Ghigo E, Maccario M (2002) Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. J Clin Endocrinol Metab 87:5052–5057PubMedCrossRef
15.
Caufriez A, Golstein J, Lebrun P, Herchuelz A, Furlanetto R, Copinschi G (1984) Relations between immunoreactive somatomedin C, insulin and T3 patterns during fasting in obese subjects. Clin Endocrinol (Oxford) 20:65–70
16.
Veldhuis JD, Iranmanesh A (1996) Physiologic regulation of the human growth hormone (GH)-insulin like growth factor type I (IGF-I) axis: predominant impact of age, obesity gonadal function, and sleep. Sleep 19(10 Suppl):S221–S224PubMed
17.
Maccario M, Ramunni J, Oleandri SE, Procopio M, Grottoli S, Rossetto R, Savio P, Aimaretti G, Camanni F, Ghigo E (1999) Relatioship between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Metab Disord 23:612–618CrossRef
18.
Gram IT, Norat T, Rinaldi S, Dossus L, Lukanova A, Tehard B, Clavel-Chapelon F, van Gils CH, van Noord PA, Peeters PH, Bueno-de-Mesquita HB, Nagel G, Linseisen J, Lahmann PH, Boeing H, Palli D, Sacerdote C, Panico S, Tumino R, Sieri S, Dorronsoro M, Quiros JR, Navarro CA, Barricarte A, Tormo MJ, Gonzalez CA, Overvad K, Paaske Johnsen S, Olsen A, Tjonneland A, Travis R, Allen N, Bingham S, Khaw KT, Stattin P, Trichopoulou A, Kalapothaki V, Psaltopoulou T, Casagrande C, Riboli E, Kaaks R (2006) Body mass index, waist circumference, and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond) 30:1623–1631CrossRef
19.
Young T, Shahar E, Nieto FJ, Redline S, Newman AB, Gottlieb DJ, Walsleben JA, Finn L, Enright P, Samet JM, Sleep Heart Health Study Research Group (2002) Prediction of sleep disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 162:893–900PubMedCrossRef
20.
Issa FG, Sullivan CE (1986) The immediate effects of nasal continuous airway pressure treatment on sleep pattern in patients with obstructive sleep apnea syndrome. Electroencephalogr Clin Neurophysiol 63:10–17PubMedCrossRef
21.
Zhang Y-S, Du J-Z (2000) The response of growth hormone and prolactin of rats to hypoxia. Neurosci Lett 279:137–140PubMedCrossRef
22.
Han RN, Han VK, Buch S, Freeman BA, Post M, Tanswell AK (1998) Insulin-like growth factor binding proteins in air and 85% oxygen-exposed adult rat lung. Am J Physiol 274:L647–L656PubMed
23.
Polo O, Berthon-Jones M, Douglas NJ, Sullivan CE (1994) Management of obstructive sleep apnoea/hypopnoea syndrome. Lancet 344:656–660PubMedCrossRef
24.
Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE (1989) Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airway pressure therapy. J Clin Endocrinol Metab 68:352–358PubMedCrossRef
25.
Cooper BG, White JE, Ashworth LA, Alberti KG, Gibson GJ (1995) Hormonal and metabolic profiles in subjects with obstructive sleep apnea syndrome and acute effect of continuous positive airway pressure (CPAP) treatment. Sleep 18:172–179PubMed
26.
Lindberg E, Berne C, Elmasry A, Hedner J, Janson C (2006) CPAP treatment of a population-based sample—what are the benefits and the treatment compliance? Sleep Med 7:553–560PubMedCrossRef
27.
Mooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P (1996) Sleep-disordered breathing in men with coronary artery disease. Chest 109:659–663PubMed
28.
Mooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P (1996) Sleep-disordered breathing in women: occurrence and association with coronary disease. Am J Med 101:251–256PubMedCrossRef
29.
Kraiczi H, Caidahl K, Samuelsson A, Peker Y, Hedner J (2001) Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest 119:1085–1091PubMedCrossRef
30.
Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P (2001) Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol 33:1777–1789PubMedCrossRef
31.
Laughlin GA, Barrett Connor E, Crıquı MH, Kritz-Silverstein D (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-I binding protein-1 levels with all-cause and cardiovascular disease mortality in older adults: The Rancho Bernardo Study. J Clin Endocrinol Metab 89:114–120PubMedCrossRef
32.
Sandhu MS (2005) Insulin-like growth factor-I and risk of type 2 diabetes and coronary heart disease: molecular epidemiology. Endocr Dev 9:44–54PubMed
33.
Poykko SM, Ukkola O, Kauma H, Kellokoski E, Horkko S, Kesaniemi A (2005) The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes. Diabetologia 48:309–316PubMedCrossRef
Metadata
Title
Low Level of IGF-1 in Obesity May Be Related to Obstructive Sleep Apnea Syndrome
Authors
Ahmet Ursavas
Mehmet Karadag
Yesim Ozarda Ilcol
Ilker Ercan
Basak Burgazlioglu
Funda Coskun
R. Oktay Gozu
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Lung / Issue 5/2007
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-007-9026-x

Other articles of this Issue 5/2007

Lung 5/2007 Go to the issue

OriginalPaper

Pulmonary Superinfection by Trichomonads in the Course of Acute Respiratory Distress Syndrome

OriginalPaper

Lung Cancer in Individuals Less Than 50 Years of Age

OriginalPaper

Association Between Heat Stress Protein 70 Induction and Decreased Pulmonary Fibrosis in an Animal Model of Acute Lung Injury

OriginalPaper

Efficacy of Corticosteroids in the Treatment of Community-Acquired Pneumonia Requiring Hospitalization

OriginalPaper

Exposure to Vehicular Pollution and Assessment of Respiratory Function in Urban Inhabitants

Report

Can We Make It Last? Maintaining Benefits Achieved with Pulmonary Rehabilitation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits